Herald staff
BOTHELL — Sonus Pharmaceuticals officials said Thursday they will refocus the company’s efforts on its drug delivery and blood substitute products and that they will drop a new drug application and halt work on the ultrasound contrast product, EchoGen.
Also, the company reported a net loss of $2.2 million, or 24 cents per share, for the third quarter compared to net income of $6.9 million, or 76 cents per share a year ago. For the first nine months of 2000, Sonus reported a net loss of $2.3 million, or 25 cents per share, compared to net income of $2.4 million, or 27 cents per share, a year ago.
Talk to us
- You can tell us about news and ask us about our journalism by emailing newstips@heraldnet.com or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to letters@heraldnet.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.